|
AVANT IMMUNOTHERA, (AVAN) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
AVANT Immunotherapeutics, Inc. engages in the discovery, development, and commercialization of products that enable human immune system to prevent and treat diseases. It is developing vaccines and therapeutics that address various applications, including cardiovascular, viral, and bacterial diseases. The companys portfolio consists of cholera and salmonella-vectored vaccine delivery technologies; Rotarix for rotavirus strain; CETi-1 for cholesterol management; VitriLife drying system for the preservation of proteins, cells, bacteria, and viruses; and TP10 for cardiac bypass surgery. AVANT has also assembled a technology platform that enables the creation of single-dose, oral vaccines for application in biodefense, travelers' vaccines, health needs, and human food safety. The company has product development and licensing agreements with GlaxoSmithKline plc; Pfizer, Inc; DynPort Vaccine Company LLC; and Lohmann Animal Health International. AVANT Immunotherapeutics was organized in 1983 and its principal executive offices are located in Needham, Massachusetts.
|
|
